Why Is COMPASS PATHWAYS ADR ADR (CMPS) Stock Moving Today?

Compass Pathways ADR (CMPS) fell 6.66% to $14.16 on Tuesday, marking a sharp reversal from its recent 14.3% gain over the past eight sessions. The stock opened with a modest 1.8% gap up but quickly declined throughout the session, hitting a low of $14.11 before closing near that level. The move followed the release of 52-week results from its Phase 3 COMP005 trial of COMP360 for treatment-resistant depression, which showed additional benefits but failed to sustain investor confidence.

What Happened

Compass Pathways reported that patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks. The company also announced the selection of Fluence to develop post-approval provider training for COMP360, pending FDA approval. Despite these developments, the stock declined sharply, with volume reaching 0.7 million shares, or 20% of its 3-month average. The stock has now printed 13 fresh 52-week lows on September 10, indicating growing retail and institutional skepticism.

Retail traders on r/wallstreetbets are calling the stock oversold, with some suggesting a rebound to $30, but no immediate catalyst has emerged to support such a move. Management is scheduled to participate in investor conferences the week of September 14, which may provide further clarity on the company’s path forward.

What The Data Shows

The stock is currently trading within its 52-week range of $4.82 to $15.87, near its 52-week low. With a market cap of $1.9 billion and a beta of 2.55, CMPS remains highly volatile. The company is unprofitable, with a trailing 12-month EPS of -3.61. Despite the recent trial data, the stock’s performance suggests investors are pricing in continued uncertainty around regulatory approval and commercial viability.

What To Watch

The week of September 14 features Compass Pathways management’s participation in three New York healthcare investor conferences. These events may offer further insight into the company’s strategy for the U.S. launch of COMP360, pending FDA approval. Investors will also monitor the coverage breadth of the recent trial data and how it influences analyst sentiment in the coming weeks.